GV

GeezerVison

The World Wide Web, restored to 800 pixels of glory.

Home|About|Gaming cabinet|Archives|How it works|Starter sites

On this site

  • Your Clinical Hub
  • News & Perspective
  • Tools & Reference
  • CME/CE
  • Video
  • Events
  • Specialties
  • Topics
  • Edition English
  • Deutsch
  • Español
  • Français
  • Português
  • UK

This view

  • Original page
  • New address

GeezerVison is showing emedicine.medscape.com — Intestinal Motility Disorders: Background, Etiology, Pathophysiology

close
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out Cancel

processing....

Tools & Reference>Gastroenterology

Intestinal Motility Disorders

Updated: Oct 23, 2025
  • Author: Mia L Manabat, DO; Chief Editor: Burt Cagir, MD, FACS  more...
  • Share
  • Print
  • Feedback
Close
  • Facebook
  • Twitter
  • LinkedIn
  • WhatsApp
  • Email
Sections
Intestinal Motility Disorders
  • Sections Intestinal Motility Disorders
  • Overview
    • Background
    • Etiology
    • Pathophysiology
    • Epidemiology
    • Prognosis
    • Patient Education
    • Show All
  • Presentation
    • History
    • Physical Examination
    • Show All
  • DDx
  • Workup
    • Approach Considerations
    • Laboratory Studies
    • Radiography and Scintigraphy
    • Manometry and Electromyography
    • Endoscopy
    • Diagnostic Laparoscopy or Laparotomy
    • Histologic Findings
    • Show All
  • Treatment
    • Approach Considerations
    • Pharmacologic Therapy
    • Endoscopy, Ostomy, and Bowel Resection
    • Diet and Activity
    • Prevention
    • Show All
  • Guidelines
  • Medication
    • Medication Summary
    • Acetylcholinesterase Inhibitors
    • Antibiotics
    • Antidiarrheals
    • Cholinergic Agonists
    • Opioid Reversal Agents
    • Prokinetic Agents
    • Secretagogues
    • Show All
  • References
Overview

Background

The phrase "intestinal motility disorders" applies to abnormal intestinal contractions, such as spasms and intestinal paralysis, and is used to describe a variety of disorders in which the gut has lost its ability to coordinate muscular activity because of endogenous or exogenous causes. [1, 2, 3] Intestinal motility disorders can be categorized as upper gastrointestinal (GI) or lower GI motility disorders.

Upper GI motility disorders include the following [4] :

  • Achalasia: Loss of esophageal peristalsis, with failure of the lower esophageal sphincter (LES) to relax
  • Gastroesophageal reflux disease (GERD): Reflux of gastric contents from the stomach into the esophagus, causing symptoms or resulting in mucosal damage
  • Gastroparesis: Delayed gastric emptying without evidence of mechanical obstruction, resulting in upper GI symptoms such as nausea, vomiting, early satiety, and abdominal pain
  • Biliary dyskinesia: Gallbladder motility disorder that results in abdominal pain in the absence of gallsones, sludge, or microlithiasis

Lower GI motility disorders include the folllowing [4, 5] :

  • Irritable bowel syndrome (diarrhea-predominant, constipation-predominant, and mixed): Chronic abdominal pain with change in bowel habits (according to Rome criteria) without an organic cause or the symptoms
  • Colonic inertia: Delayed passage of stool through the colon without abnormalities in the defecation process, which results in constipation
  • Intestinal pseudo-obstruction (Ogilvie syndrome): Acute severe colonic dilatation without an anatomic obstruction or process
  • Pelvic floor dyssynergia: A functional obstruction from impaired relaxation of the puborectalis muscle, the external anal sphincter, or both, resulting in a decrease in the anorectal angle and causing difficulty in evacuation of stool
  • Hirschsprung disease: Also known as congenital aganglionic megacolon, in which the distal section of the colon that is missing ganglion cells fails to relax, causing a functional obstruction
  • Fecal incontinence: Involuntary leakage of stool

Upper intestinal motility disorders may manifest as the following:

  • Abdominal distention
  • Severe abdominal colicky pain
  • GERD
  • Intractable or recurrent nausea or vomiting

Lower intestinal motility disorders may manifest as the following:

  • Recurrent obstruction
  • Severe abdominal colicky pain
  • Severe constipation
  • Diarrhea
  • Stool incontinence
eMedicine Logo
Next:

Etiology

Causes of intestinal motility disorders appear to be multifactorial, and only a few have been identified.

Achalasia

Studies on primary achalasia suggest it is primarily an autoimmune disorder. Worldwide, the most common cause of secondary achalasia is Trypanosoma cruzi infection (Chagas disease); another cause is iatrogenic (ie, surgical error in forming fundoplication or gastric banding). [6] Systemic diseases that infiltrate the lower esophageal sphincter can cause a pseudoachalasia, such as tumors of the gastroesophageal junction or gastric cardia and amyloidosis.

Gastroesophageal reflux disease

Many different factors can attribute to gastroesophageal reflux disease (GERD). These include but are not limited to transient lower esophageal relaxations, weak lower esophageal sphincter, delayed gastric emptying, increased gastric acid production, hiatal hernia, and obesity. [7]

Gastroparesis

The most common etiologies of gastroparesis noted in tertiary care centers include idiopathic (36%), diabetes mellitus (29%), and postsurgical (13%). [8] Less common etiologies include postviral and opioid-induced gastroparesis. Rare causes include paraneoplastic syndrome, Parkinson disease, amyloidosis, and scleroderma.

Biliary dyskinesia

The exact etiology of biliary dyskinesia is unknown.

Irritable bowel syndrome

The causes of irritable bowel syndrome (IBS) remain unknown. According to some reports, the small intestine and colon of patients with IBS are more sensitive and reactive to mild stimuli than usual. IBS may be related to the immature status of muscles and nerves in the intestinal wall of affected persons.

Colonic inertia

The underlying etiology of colonic inertia appears to be dysfunction of the enteric nerve plexus. It has been suggested that patients have a decreased number or complete absence of interstitial cells of Cajal. [9]

Intestinal pseudo-obstruction (Ogilvie syndrome)

The exact etiology of acute colonic pseudo-obstruction is unknown. It has been hypothesized that a dysregulation of nerve impulses in the enteric nervous system results in a large bowel obstruction without an actual physical obstruction. The inciting event is most commonly postsurgical, cardiopulmonary conditions, metabolic disorders, and trauma, among many other reported causes. [10]

Pelvic floor dyssynergia

Pelvic floor dyssynergia and pelvic floor dysfunction are caused by impaired relaxation of the external anal sphincter, impaired relaxation of the puborectalis muscle, or decreased propulsion of stool through the colon. Similar to other motility disorders, there is an underlying dysfunction of nerve conduction. Defecation specifically involves coordination of the enteric, parasympathetic, and sympathetic nervous systems.

Hirschsprung disease

Hirschsprung disease is a congenital disorder that results from absence of ganglion cells in a portion of the colon, most commonly the rectosigmoid colon. This is caused by a failure of neural crest cells to migrate during fetal development. Several genetic mutations have also been found to be associated with Hirschsprung disease. [11]

Fecal incontinence

Aging, dementia, stroke, Parkinson disease, spinal cord injuries, rectal tears during birthing, diabetes, surgical complications, and neuromuscular disorders (eg, myasthenia gravis) may cause fecal incontinence.

Occasionally, fecal incontinence may occur after ingestion of certain foods. Sugars, insoluble fibers, and starches (except rice) are broken down in the intestines, forming a variable amount of gas that must be expelled. Most people who have lactase deficiency cannot digest lactose, a sugar common in several foods (eg, milk, cakes). People who have lactose deficiency may experience uncontrolled liquid diarrhea after lactose ingestion.

Constipation

Constipation commonly has several causes, either primary or secondary. The most frequent of these are the following:

  • Diet that is very poor in fiber and high in animal fats and refined sugars
  • Pregnancy
  • Psychological constipation related to lifestyle changes (eg, travel, a new job, or divorce), in which the patient ignores the urge to defecate
  • Hypothyroidism
  • Electrolyte imbalance, especially if it involves Ca++ or K+
  • Tumors producing mechanical compression on an intestinal tract, either internally or externally
  • Nervous system injuries
  • Intoxication from lead, mercury, phosphorus, or arsenic
  • Constipation also may be secondary to rhagades (anal fissures) and piles.

 

eMedicine Logo
Previous
Next:

Pathophysiology

Coordinated movements of the stomach and intestines are required to digest and propel intestinal contents along the digestive tract. The complex patterns of contraction and relaxation necessary for proper motility of the gastrointestinal (GI) tract are generated in the nerves and muscles within the GI walls.

Every day, at any time, many factors can influence GI motility (eg, physical exercise, emotional distress). The pathogenesis of primary intestinal motility disorders probably is multifactorial, but neither biochemical abnormality nor structural abnormality has been demonstrated commonly, except in some forms of intestinal pseudo-obstruction. More recently, there is evidence that low-grade mucosal inflammation and immune activation (particularly with mast cell involvement) in association with impaired epithelial barrier function and aberrant neuronal sensitivity may play a role in functional GI disorders. [12]

Although the overall structural organization is similar throughout the digestive tract, each part has distinct motor activities. The musculature of the digestive tract has either extrinsic innervation (both sympathetic and parasympathetic) or intrinsic innervation (Auerbach plexus or myenteric plexus).

Intrinsic innervation is fundamental to coordinating GI motor activity. A neural network branching between longitudinal and circular muscle layers of the GI tract constitutes intrinsic innervation. Another nervous intrinsic plexus in the GI tract (Meissner plexus or submucosal plexus) helps to modify mucosal absorption and secretion without influencing motility.

Random, unorganized motor activity with occasional peristaltic and antiperistaltic complexes occurs during feeding, and this allows gastric remixing of foods. After this, another motor activity occurs, which is more regular, and this begins the peristaltic waves (ie, contractions of the circular musculature of the small intestine) that allow progression of undigested food through the intestines.

These events happen because the gastric pacemaker area, which originates electric slow waves with a frequency of 3 cycles per minute, occurs at the junction between the body and the antrum of the stomach. These electric waves, called migrating myoelectric complexes, determine the frequency of muscular contractions in the antral and pyloric areas through electromechanical coupling.

Migrating myoelectric complexes regulate gastric emptying and move gastric contents distally. Every 90 minutes, a cluster of migrating myoelectric complexes arises in the stomach and migrates distally beyond the ileum. Vagal function and the release of nitric oxide, vasoactive intestinal polypeptide, motilin, and nutrients of the meal and other enterohormones also affect GI motility.

Knowles and Martin attempted to define a novel classification for intestinal motility disorders, [13] in which these conditions are categorized as well-defined entities, entities with a variable dysfunction-symptom relation, questionable entities, and entities associated with behavioral disorders.

Well-defined entities in the Knowles-Martin classification include the following:

  • Delayed colonic transit: Slow transit constipation (eg, enteric neuropathy, enteric myopathy, Parkinson disease, endocrine disorders, spinal injury); the impairment of gastric motility in Parkinson disease patients, particularly in those with motor complications (42%), may be due in part to the effect of L-dopa on gastric dopaminergic receptors [14] ; in patients with spina bifida and spinal cord injuries, altered histology of the enteric nervous system as well as myenteric plexus neuronal loss and decreased nerve fiber density may play a major role in intestinal motility [15]
  • Dilated colon (diffuse or segmental) - Ogilvie syndrome, megacolon
  • Absent rectoanal inhibitory reflex: Hirschsprung disease

Entities with a variable dysfunction-symptom relation include the following:

  • Abnormally low anal canal pressure fecal incontinence (eg, diabetes mellitus, spinal injury)

Questionable entities include the following:

  • Accelerated transit bile salts
  • Short bowel
  • Rare endocrine and metabolic disorders

Entities associated with behavioral disorders include the following:

  • Impaired pelvic floor relaxation, prolonged storage in the rectosigmoid, outlet delay, anismus
  • Avoidance of defecation, functional fecal retention (eg, poor pelvic floor training, poor diet, fear of pain, learned suppression)
eMedicine Logo
Previous
Next:

Epidemiology

According to some epidemiologic reports, as many as 30 million Americans have intestinal motility disorders. Available data from the medical literature indicate that worldwide, 30-45% of all gastrointestinal conditions are referable to intestinal motility disorders.

When intestinal motility disorders are idiopathic and not related to either malignancies or systemic diseases, morbidity is minimal and mortality from complications is low (1-1.5%); complications usually occur in patients with intestinal pseudo-obstruction.

Persons of any age group may be affected, depending on the specific intestinal motility disorder. For example, IBS occurs more frequently in people aged 20-40 years, whereas intestinal pseudo-obstruction may occur in either newborns or elderly patients. Most patients are female, with a female-to-male ratio of 2.8:1. Primary intestinal motility disorders are most common in white persons and are usually thought to be related to diet.

eMedicine Logo
Previous
Next:

Prognosis

Primary intestinal motility disorders or disorders that are not secondary to malignancy or debilitating pathology have a good prognosis. According to many reports, the prognosis is excellent for patients with irritable bowel syndrome and mild fecal incontinence.

The prognosis is worse for patients with intestinal pseudo-obstruction, which has a high mortality.

Complications

Complications of intestinal motility disorders vary greatly, depending on the specific type of disorder under consideration.

Intestinal pseudo-obstruction is often associated with a high mortality (15-30%), in most cases due to delayed diagnosis.

Constipation may have a severe complication, impaction. If this condition is not recognized early, the patient may die. Impaction is the collection of dry and hardened feces in the rectum or colon. Symptoms of impaction may be similar to those of constipation or may be unrelated to the gastrointestinal system.

If abdominal distention occurs, movements of the diaphragm are compromised and cause insufficient aeration with subsequent hypoxia and left ventricular dysfunction. In addition, hypoxia can precipitate angina or tachycardia. When a vasovagal response begins, the patient may have hypotension. Patients with impaction may experience vomiting, diarrhea, and resultant dehydration. They may present in an acutely confused and disoriented state, with tachycardia, fever, and altered blood pressure.

Irritable bowel syndrome is not usually associated with complications. Fecal incontinence may cause psychological problems in affected patients.

eMedicine Logo
Previous
Next:

Patient Education

Patients with intestinal motility disorders must be educated in ways of coping with their condition and instructed to avoid any situation or substance that may cause the symptoms to worsen. Psychological counseling may be helpful.

Patient support groups, such as the Association of Gastrointestinal Motility Disorders, Cyclic Vomiting Syndrome Association, Gastroparesis Patient Association for Cures and Treatment, International Foundation for Gastrointestinal Disorders, and IBS Patient Support Group provide advice, information, educational meetings, and psychological support to patients and their families.

eMedicine Logo
Previous
Clinical Presentation
 
 
References
Disclaimer: This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
  1. Di Lorenzo C, Youssef NN. Diagnosis and management of intestinal motility disorders. Semin Pediatr Surg. 2010 Feb. 19(1):50-8. [QxMD MEDLINE Link].

  2. Keller J, Layer P. Intestinal and anorectal motility and functional disorders. Best Pract Res Clin Gastroenterol. 2009. 23(3):407-23. [QxMD MEDLINE Link].

  3. Venkatasubramani N, Sood MR. Motility disorders of the gastrointestinal tract. Indian J Pediatr. 2006 Oct. 73(10):927-30. [QxMD MEDLINE Link].

  4. Ouyang A, Locke GR 3rd. Overview of neurogastroenterology-gastrointestinal motility and functional GI disorders: classification, prevalence, and epidemiology. Gastroenterol Clin North Am. 2007 Sep. 36(3):485-98, vii. [QxMD MEDLINE Link].

  5. Rao SS. Constipation: evaluation and treatment of colonic and anorectal motility disorders. Gastroenterol Clin North Am. 2007 Sep. 36(3):687-711, x. [QxMD MEDLINE Link].

  6. Rozman RW Jr, Achkar E. Features distinguishing secondary achalasia from primary achalasia. Am J Gastroenterol. 1990 Oct. 85(10):1327-30. [QxMD MEDLINE Link].

  7. Labenz J, Jaspersen D, Kulig M, et al. Risk factors for erosive esophagitis: a multivariate analysis based on the ProGERD study initiative. Am J Gastroenterol. 2004 Sep. 99(9):1652-6. [QxMD MEDLINE Link].

  8. Hyett B, Martinez FJ, Gill BM, et al. Delayed radionucleotide gastric emptying studies predict morbidity in diabetics with symptoms of gastroparesis. Gastroenterology. 2009 Aug. 137(2):445-52. [QxMD MEDLINE Link].

  9. Shafik A, Shafik AA, El-Sibai O, Shafik IA. Interstitial cells of cajal in patients with constipation due to total colonic inertia. J Invest Surg. 2006 May-Jun. 19(3):147-53. [QxMD MEDLINE Link].

  10. Chudzinski AP, Thompson EV, Ayscue JM. Acute colonic pseudoobstruction. Clin Colon Rectal Surg. 2015 Jun. 28(2):112-7. [QxMD MEDLINE Link].[Full Text].

  11. Amiel J, Sproat-Emison E, Garcia-Barcelo M, et al, for the Hirschsprung Disease Consortium. Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet. 2008 Jan. 45(1):1-14. [QxMD MEDLINE Link].[Full Text].

  12. Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders. Gut. 2016 Jan. 65(1):155-68. [QxMD MEDLINE Link].

  13. Knowles CH, Martin JE. Slow transit constipation: a model of human gut dysmotility. Review of possible aetiologies. Neurogastroenterol Motil. 2000 Apr. 12(2):181-96. [QxMD MEDLINE Link].

  14. Bestetti A, Capozza A, Lacerenza M, Manfredi L, Mancini F. Delayed gastric emptying in advanced Parkinson disease: correlation with therapeutic doses. Clin Nucl Med. 2017 Feb. 42(2):83-7. [QxMD MEDLINE Link].

  15. den Braber-Ymker M, Lammens M, van Putten MJ, Nagtegaal ID. The enteric nervous system and the musculature of the colon are altered in patients with spina bifida and spinal cord injury. Virchows Arch. 2017 Feb. 470(2):175-84. [QxMD MEDLINE Link].[Full Text].

  16. [Guideline] Malagelada C, Keller J, Sifrim D, et al. European Guideline on Chronic Nausea and Vomiting-A UEG and ESNM Consensus for Clinical Management. United European Gastroenterol J. 2025 Apr. 13 (3):427-71. [QxMD MEDLINE Link].[Full Text].

  17. Li B, Wang JR, Ma YL. Bowel sounds and monitoring gastrointestinal motility in critically ill patients. Clin Nurse Spec. 2012 Jan. 26(1):29-34. [QxMD MEDLINE Link].

  18. [Guideline] Keller J, Bassotti G, Clarke J, et al, for the International Working Group for Disorders of Gastrointestinal Motility and Function. Expert consensus document: Advances in the diagnosis and classification of gastric and intestinal motility disorders. Nat Rev Gastroenterol Hepatol. 2018 May. 15 (5):291-308. [QxMD MEDLINE Link].[Full Text].

  19. Remes-Troche JM, Rao SS. Diagnostic testing in patients with chronic constipation. Curr Gastroenterol Rep. 2006 Oct. 8(5):416-24. [QxMD MEDLINE Link].

  20. [Guideline] Tack J, Vanuytsel T, Serra J, et al, for the ESNM Consensus Group, the Leuven Consensus Group, et al. European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic. Neurogastroenterol Motil. 2020 Jul. 32 (7):e13930. [QxMD MEDLINE Link].[Full Text].

  21. Centers for Disease Control and Prevention. 2025-2026 Respiratory Disease Season Outlook. CFA: Qualitative Assessments. Available athttps://www.cdc.gov/cfa-qualitative-assessments/php/data-research/season-outlook25-26.html. August 25, 2025; Accessed: October 23, 2025.

  22. Maqbool S, Parkman HP, Friedenberg FK. Wireless capsule motility: comparison of the SmartPill GI monitoring system with scintigraphy for measuring whole gut transit. Dig Dis Sci. 2009 Oct. 54(10):2167-74. [QxMD MEDLINE Link].

  23. [Guideline] American College of Radiology (ACR), the Society of Nuclear Medicine (SNM), and the Society for Pediatric Radiology (SPR). ACR–SNM–SPR Practice parameter for the performance of gastrointestinal scintigraphy. Res. 29 – 2010, Amended 2014 (Res. 39). ACR American College of Radiology. Available athttps://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2010/GI_Scintigraphy_1382731852503_4.pdf. Revised 2010; Accessed: October 29, 2014.

  24. [Guideline] ACR–ACNM–SNMMI–SPR Practice parameter for the performance of gastrointestinal tract, hepatic, and splenic scintigraphy. Resolution 16. Rev 2020. [Full Text].

  25. Alyami J, Spiller RC, Marciani L. Magnetic resonance imaging to evaluate gastrointestinal function. Neurogastroenterol Motil. 2015 Dec. 27(12):1687-92. [QxMD MEDLINE Link].

  26. Burns AJ. Disorders of interstitial cells of Cajal. J Pediatr Gastroenterol Nutr. 2007 Dec. 45(Suppl 2):S103-6. [QxMD MEDLINE Link].

  27. He CL, Burgart L, Wang L, Pemberton J, Young-Fadok T, Szurszewski J, et al. Decreased interstitial cell of cajal volume in patients with slow-transit constipation. Gastroenterology. 2000 Jan. 118(1):14-21. [QxMD MEDLINE Link].

  28. Pardi DS, Miller SM, Miller DL, et al. Paraneoplastic dysmotility: loss of interstitial cells of Cajal. Am J Gastroenterol. 2002 Jul. 97(7):1828-33. [QxMD MEDLINE Link].

  29. Sanders KM. Interstitial cells of Cajal at the clinical and scientific interface. J Physiol. 2006 Nov 1. 576(Pt 3):683-7. [QxMD MEDLINE Link].

  30. Vanuytsel T, Tack JF, Boeckxstaens GE. Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol. 2014 Aug. 49(8):1193-205. [QxMD MEDLINE Link].

  31. [Guideline] Weusten BLAM, Barret M, Bredenoord AJ, et al. Endoscopic management of gastrointestinal motility disorders - part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2020 Jun. 52 (6):498-515. [QxMD MEDLINE Link].[Full Text].

  32. [Guideline] Weusten BLAM, Barret M, Bredenoord AJ, et al. Endoscopic management of gastrointestinal motility disorders - part 2: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2020 Jul. 52 (7):600-14. [QxMD MEDLINE Link].[Full Text].

  33. Fu A. Neostigmine: an alternative treatment for constipation. Dynamics. 2005. 16(1):13-5. [QxMD MEDLINE Link].

  34. Karamanolis G, Tack J. Promotility medications--now and in the future. Dig Dis. 2006. 24(3-4):297-307. [QxMD MEDLINE Link].

  35. Sarna SK. Molecular, functional, and pharmacological targets for the development of gut promotility drugs. Am J Physiol Gastrointest Liver Physiol. 2006 Oct. 291(4):G545-55. [QxMD MEDLINE Link].

  36. Quigley EM. Prucalopride: safety, efficacy and potential applications. Therap Adv Gastroenterol. 2012 Jan. 5(1):23-30. [QxMD MEDLINE Link].[Full Text].

  37. Malagelada C, Nieto A, Mendez S, Accarino A, Santos J, Malagelada JR, et al. Effect of prucalopride on intestinal gas tolerance in patients with functional bowel disorders and constipation. J Gastroenterol Hepatol. 2017 Aug. 32(8):1457-62. [QxMD MEDLINE Link].

  38. Bassotti G, Gambaccini D, Bellini M. Prucalopride succinate for the treatment of constipation: an update. Expert Rev Gastroenterol Hepatol. 2016. 10(3):291-300. [QxMD MEDLINE Link].

  39. Saunders MD, Kimmey MB. Systematic review: acute colonic pseudo-obstruction. Aliment Pharmacol Ther. 2005. 22(10):917. [QxMD MEDLINE Link].[Full Text].

  40. Mellgren A, Matzel KE, Pollack J, et al, for the Nasha Dx Study Group. Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence. Neurogastroenterol Motil. 2014 Aug. 26(8):1087-94. [QxMD MEDLINE Link].[Full Text].

  41. Mazzone A, Farrugia G. Evolving concepts in the cellular control of gastrointestinal motility: neurogastroenterology and enteric sciences. Gastroenterol Clin North Am. 2007 Sep. 36(3):499-513, vii. [QxMD MEDLINE Link].

  42. Parthasarathy G, Ravi K, Camilleri M, et al. Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders. Neurogastroenterol Motil. 2015 Dec. 27(12):1736-46. [QxMD MEDLINE Link].[Full Text].

Media Gallery
  • Intestinal Motility Disorders. This radiograph reveals a dilated cecum (16 cm) and colon in a patient with pseudocolonic obstruction.
of 1
Tables
    Back to List
    Contributor Information and Disclosures
    Author

    Mia L Manabat, DO Gastroenterologist, Aurora Health Care

    Mia L Manabat, DO is a member of the following medical societies: American College of Osteopathic Internists, American Osteopathic Association

    Disclosure: Nothing to disclose.

    Coauthor(s)

    Michael H Piper, MD Clinical Assistant Professor, Department of Internal Medicine, Division of Gastroenterology, Wayne State University School of Medicine; Consulting Staff, Digestive Health Associates, PLC

    Michael H Piper, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Gastroenterology, American College of Physicians, Michigan State Medical Society

    Disclosure: Nothing to disclose.

    Chief Editor

    Burt Cagir, MD, FACS Associate Regional Dean and Professor of Surgery, Geisinger Commonwealth School of Medicine; Director, General Surgery Residency Program, Executive Director, Donald Guthrie Foundation for Research and Education, Guthrie Robert Packer Hospital; Medical Director, Guthrie/RPH Skills and Simulation Lab; Associate in Surgery, Guthrie Robert Packer Hospital and Corning Hospital

    Burt Cagir, MD, FACS is a member of the following medical societies: American College of Surgeons, Association of Program Directors in Surgery, Society for Surgery of the Alimentary Tract

    Disclosure: Nothing to disclose.

    Additional Contributors

    Vivek V Gumaste, MD Associate Professor of Medicine, Mount Sinai School of Medicine of New York University; Adjunct Clinical Assistant, Mount Sinai Hospital; Director, Division of Gastroenterology, City Hospital Center at Elmhurst; Program Director of GI Fellowship (Independent Program); Regional Director of Gastroenterology, Queens Health Network

    Vivek V Gumaste, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association

    Disclosure: Nothing to disclose.

    Nafisa Kuwajerwala Goswami, MD Staff Surgeon, Breast Care Center, William Beaumont Hospital

    Nafisa Kuwajerwala Goswami, MD is a member of the following medical societies: American College of Surgeons, American Society of Breast Surgeons, American Society of Breast Disease

    Disclosure: Nothing to disclose.

    Luigi Santacroce, MD Assistant Professor, Medical School, State University at Bari, Italy

    Disclosure: Nothing to disclose.

    Venkata Subramanian Kanthimathinathan, MD Fellow in Bariatric/Advanced Laparoscopic Surgery, University of Missouri Healthcare

    Disclosure: Nothing to disclose.

    Acknowledgements

    Silvia Gagliardi, MD Consulting Staff, Department of Surgery, Medical Center Vita, Italy

    Disclosure: Nothing to disclose.

    Douglas M Heuman, MD, FACP, FACG, AGAF Chief of GI, Hepatology, and Nutrition at North Shore University Hospital/Long Island Jewish Medical Center; Professor, Department of Medicine, Hofstra North Shore-LIJ School of Medicine

    Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, and American Gastroenterological Association

    Disclosure: Novartis Grant/research funds Other; Bayer Grant/research funds Other; Otsuka Grant/research funds None; Bristol Myers Squibb Grant/research funds Other; Scynexis None None; Salix Grant/research funds Other; MannKind Other

    Sandeep Mukherjee, MB, BCh, MPH, FRCPC Associate Professor, Department of Internal Medicine, Section of Gastroenterology and Hepatology, University of Nebraska Medical Center; Consulting Staff, Section of Gastroenterology and Hepatology, Veteran Affairs Medical Center

    Sandeep Mukherjee, MB, BCh, MPH, FRCPC is a member of the following medical societies: Royal College of Physicians and Surgeons of Canada

    Disclosure: Merck Honoraria Speaking and teaching; Ikaria Pharmaceuticals Honoraria Board membership

    Shivkumar Prabhu, MD Consulting Staff, Department of Internal Medicine, St John Detroit Riverview Hospital

    Disclosure: Nothing to disclose.

    Daniel Schafer Department of Surgery, University of Nebraska Medical Center

    Disclosure: Nothing to disclose.

    Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

    Disclosure: Medscape Salary Employment

    Close
    What would you like to print?
    What would you like to print?
    • Print this section
    • Print the entire contents of
    • Print the entire contents of article
    • Sections Intestinal Motility Disorders
    • Overview
      • Background
      • Etiology
      • Pathophysiology
      • Epidemiology
      • Prognosis
      • Patient Education
      • Show All
    • Presentation
      • History
      • Physical Examination
      • Show All
    • DDx
    • Workup
      • Approach Considerations
      • Laboratory Studies
      • Radiography and Scintigraphy
      • Manometry and Electromyography
      • Endoscopy
      • Diagnostic Laparoscopy or Laparotomy
      • Histologic Findings
      • Show All
    • Treatment
      • Approach Considerations
      • Pharmacologic Therapy
      • Endoscopy, Ostomy, and Bowel Resection
      • Diet and Activity
      • Prevention
      • Show All
    • Guidelines
    • Medication
      • Medication Summary
      • Acetylcholinesterase Inhibitors
      • Antibiotics
      • Antidiarrheals
      • Cholinergic Agonists
      • Opioid Reversal Agents
      • Prokinetic Agents
      • Secretagogues
      • Show All
    • References
    encoded search term (Intestinal Motility Disorders) and Intestinal Motility Disorders
    What to Read Next on Medscape
    Related Conditions and Diseases
    • Irritable Bowel Syndrome (IBS)
    • Advances in Treatment of Irritable Bowel Syndrome With Constipation
    • Irritable Bowel Syndrome Diagnostic Criteria (Manning Criteria)
    • Worsening Abdominal Pain and Bloating in a 30-Year-Old Woman
    • FDA Approvals, Highlights, and Summaries: Gastroenterology
    • Patient Simulation: A 55-Year-Old Woman With Orthostasis and Worsening Paresthesia
    • Intestinal Motility Disorders
    News & Perspective
    • Irritable Bowel Syndrome Relieved by Low-dose Amitriptyline
    • Which Probiotics Are Effective in Irritable Bowel Syndrome?
    • Study Maps Genes Tied to Targets in Irritable Bowel Syndrome
    • Inside Diverticulitis: What Gastroenterologists Need to Know Inside Diverticulitis: What Gastroenterologists Need to Know
    • Beyond Laxatives: Emerging Ways to Manage Constipation Beyond Laxatives: Emerging Ways to Manage Constipation
    • medical-mentor_thumb Celiac Disease: Unmasking the Great Imitator
    Tools
    • Drug Interaction Checker
    • Calculators
    • Formulary
    Slideshow
    10 Gynecologic Emergencies: When and How to Manage Them FDA Drug Approvals and Changes: June Edition FDA Drug Approvals and Changes: June Edition
    Recommended
    • 2002 180389-overview Diseases & Conditions
      Diseases & Conditions Irritable Bowel Syndrome (IBS) Irritable Bowel Syndrome (IBS)
    • 2001 https://www.medscape.com/viewarticle/irritable-bowel-syndrome-relieved-low-dose-amitriptyline-2023a1000pmg news
      news Irritable Bowel Syndrome Relieved by Low-dose Amitriptyline
    • 2001 https://www.medscape.com/viewarticle/which-probiotics-are-effective-irritable-bowel-syndrome-2024a10007o4 news
      news Which Probiotics Are Effective in Irritable Bowel Syndrome?
    • 2001 https://www.medscape.com/viewarticle/study-maps-genes-tied-targets-irritable-bowel-syndrome-2025a1000xzx news
      news Study Maps Genes Tied to Targets in Irritable Bowel Syndrome
    • 2001 /viewarticle/1003090
      Celiac Disease: Unmasking the Great Imitator
    • 2010 https://reference.medscape.com/calculator/irritable-bowel-syndrome-criteria
      Irritable Bowel Syndrome Diagnostic Criteria (Manning Criteria)
    You are visitor 01402503 — GeezerVison does not store the pages you look up.
    Best viewed with Netscape Navigator 4.7 or Internet Explorer 6 at 800×600. No cookies required.